Ticho Barry sold $190K of STOK

Ticho Barry (CHIEF MEDICAL OFFICER) sold 7,195 shares of Stoke Therapeutics, Inc. (STOK) at an average of $26.40 ($26.38–$26.99, $0.19M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ticho Barry
Published Nov 4, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STOK
Neutral
high confidence
Mentioned
$STOK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKNeutralLow
01

Why it matters

The disclosed sale is modest in size but provides fresh data on insider sentiment.

02

Market read

New insider sale information may influence short‑term trading decisions for STOK.

03

What to watch

Potential upcoming clinical milestones for Stoke Therapeutics may offset short‑term pressure.

Relevance 3/10Novelty 3/10Timing: after‑hours filing today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$STOKNeutralHigh confidence
Context

Chief Medical Officer Ticho Barry sold 7,195 shares for $189,912 via a 10b5‑1 plan, reducing his stake to 11,864 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

A recent Form 4 filing shows a C‑suite insider disposing of nearly $190 k of stock, which typically signals limited confidence and can prompt short‑term price softness.

Market effects

none

none

none

Counterpoint

The sale could be routine liquidity management and not indicative of future performance.

Key entities

  • Stoke Therapeutics, Inc.

    Biopharma company developing therapeutic candidates.

  • Ticho Barry

    Chief Medical Officer of Stoke Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.